Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.54 |
| ▸ | PTGFR | P43088 | 1/20 | 0.54 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.52 |
| ▸ | PPARG | P37231 | 7/20 | 0.52 |
| ▸ | PPARD | Q03181 | 7/20 | 0.52 |
| ▸ | PPARA | Q07869 | 7/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11770922 | 1.00 | ALOX5 (0.59) | ALOX5TBXA2RPTGFRPTGER2GPR84 | |
| SCHEMBL9623088 | 1.00 | ALOX5 (0.59) | ALOX5TBXA2RPTGFRPTGER2GPR84 | |
| SCHEMBL11039601 | 1.00 | ALOX5 (0.59) | ALOX5TBXA2RPTGFRPTGER2GPR84 | |
| Rosaprostol SCHEMBL186775 | 1.00 | ALOX5 (0.59) | ALOX5TBXA2RPTGFRPTGER2GPR84 | |
| SCHEMBL11186080 | 1.00 | ALOX5 (0.59) | ALOX5TBXA2RPTGFRPTGER2GPR84 | |
| Rosaprostol SCHEMBL1231120 | 0.98 | ALOX5 (0.58) | ALOX5TBXA2RPTGFRPTGER2GPR84 | |
| SCHEMBL11729161 | 0.92 | KMT2A (0.54) | ALOX5TBXA2RPTGFRPTGER2GPR84 | |
| SCHEMBL11655265 | 0.92 | KMT2A (0.54) | ALOX5TBXA2RPTGFRPTGER2GPR84 | |
| SCHEMBL9808452 | 0.91 | ALOX5 (0.56) | ALOX5TBXA2RPTGFRPTGER2GPR84 | |
| SCHEMBL9808378 | 0.91 | ALOX5 (0.56) | ALOX5TBXA2RPTGFRPTGER2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 929 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3895686-B1 | NATURAL COMPOSITION FOR HAIR GROWTH STIMULATION AND HAIR LOSS PREVENTION AND TREATMENT | FRAUNHOFER GES FORSCHUNG (DE) | 2025-04-09 | — | — | EP | claimed |
| WO-2021209442-A1 | NATURAL COMPOSITION FOR HAIR GROWTH STIMULATION AND HAIR LOSS PREVENTION AND TREATMENT | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. (DE) | 2021-10-21 | — | — | WO | claimed |
| WO-2021209437-A1 | NATURAL COMPOSITION FOR HAIR GROWTH STIMULATION AND HAIR LOSS PREVENTION AND TREATMENT WITHOUT PRESERVATIVES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. (DE) | 2021-10-21 | — | — | WO | claimed |
| EP-3895685-A1 | NATURAL COMPOSITION FOR HAIR GROWTH STIMULATION AND HAIR LOSS PREVENTION AND TREATMENT WITHOUT PRESERVATIVES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2021-10-20 | — | — | EP | claimed |
| EP-3895686-A1 | NATURAL COMPOSITION FOR HAIR GROWTH STIMULATION AND HAIR LOSS PREVENTION AND TREATMENT | FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. (DE) | 2021-10-20 | — | — | EP | claimed |
| EP-3852608-A1 | COMPOSITIONS AND METHODS FOR GLAUCOMA | Aufbau Medical Innovations Limited (IE) | 2021-07-28 | — | — | EP | claimed |
| WO-2020061550-A1 | COMPOSITIONS AND METHODS FOR GLAUCOMA | AUFBAU MEDICAL INNOVATIONS LIMITED (IE) | 2020-03-26 | — | — | WO | claimed |
| CN-108863787-A | 3- alkyl -2- carbethoxyl group substituted cyclic is conjugated asymmetric catalytic hydrogenation and its application of ketenes | 南开大学 | 2018-11-23 | — | — | CN | claimed |
| US-9622963-B2 | Methods for stimulating growth and preventing loss of human hair | NNC BLENDING LLC (US) | 2017-04-18 | — | — | US | claimed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | claimed |
| WO-2000051978-A1 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METODS OF USE | NITROMED, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| EP-1032605-A1 | POLYANHYDRIDES WITH THERAPEUTICALLY USEFUL DEGRADATION PRODUCTS | Rutgers, The State University (US) | 2000-09-06 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1999047497-A2 | CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK FROSST CANADA & CO. (CA) | 1999-09-23 | — | — | WO | claimed |
| WO-1999012990-A1 | POLYANHYDRIDES WITH THERAPEUTICALLY USEFUL DEGRADATION PRODUCTS | RUTGERS, THE STATE UNIVERSITY (US) | 1999-03-18 | — | — | WO | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| EP-0769953-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CO-DRIED SUCRALFATE GEL AND POLYALCOHOL | ENOSYS S.A. (CH) | 1997-05-02 | — | — | EP | claimed |
| WO-1996005843-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CO-DRIED SUCRALFATE GEL AND POLYALCOHOL | ENOSYS S.A. (CH) | 1996-02-29 | — | — | WO | claimed |
| EP-0155392-B1 | IMPROVED PROCESSES FOR PREPARING 7-(2-HEXYL-5-HYDROXY-CYCLOPENTYL)-HEPTANOIC ACID | IBI- Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. (IT) | 1990-05-02 | — | — | EP | claimed |
| US-4894473-A | MULTISTAGE, REACTION OF AZELAIC ACID MONOESTER, 9-KETONE-12-NITRODECANOIC ACID, METHYL ESTER INTERMEDIATES | ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.P.A. (IT) | 1990-01-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | ALOX5 112/4885TBXA2R 181/4885PTGFR 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.